基本介紹
- 中文名：龔笑海
- 學位/學歷：博士
- 職業：教師
- 專業方向：藥學/藥劑學
- 任職院校：江南大學
個人經歷,研究方向,學術成果,
個人經歷
【學習和工作經歷】
2015.1-至今Wuxi Paribio Inc.Wuxi, China
Founder, Executive board director, CSO
2010.2-2015.1 Wuxi BioHermes Inc.MaShan, Wuxi, China
Founder, Executive board director, CSO
1999.11-2010.1 Wyeth Pharmaceuticals, (Acquired by Pfizer 2009)Princeton, NJ
Sr. Research Scientist II (group leader)
1997.4-1999.10 Lexicon Pharmaceuticals, Woodlands, TX
Sr. Research Scientist I (PhD level, project leader)
1990.9-1997.3 UT MD Anderson Cancer Center,Houston, TX
Sr. Research Scientist (lab manager)
1983.8-1990.9Shanghai institute of Biochemistry, Chinese Academy of Science
Sr. Research scientist
1.
1.創辦了無錫博慧斯（BioHermes）生物醫藥科技有限公司創辦人兼技術總工
尤以體外檢測見長，研發並申報有國際專利的博唐平A1C EZ（糖化血紅蛋白檢測儀），2014年估值3億人民幣；
2.創辦了江蘇愛爾康（EyeCure）生物醫藥科技有限公司創辦人兼技術總工
國際眼科細胞和基因治療領跑者，實現了人源RPE細胞的臨床治療老年性視網膜黃斑變性等疾病，2018年估值2億人民幣。
研究方向
藥學/藥劑學
學術成果
學科建設方面
龔笑海教授於2014年首次發起並組織了國際生物醫藥產學研論壇在無錫江南大學藥學院的召開，該論壇每年邀請國際前言生物醫藥研究者對國際醫藥產業的前言進行深度剖析，對生物製藥人才的培養模式具有十分重要的意義。龔笑海教授負責每年參會人員的邀請及會議的主持，隨著影響力度的加大，現由江南大學、無錫市食品藥品監督管理局以及無錫市對外科技交流中心共同主辦，截止目前國際生物醫藥產學研論壇已經召開四屆（2014-2017），對我校的生物醫藥學科建設起到了積極導向作用。
近年來主要及協助研究課題
[1]PARP抑制劑類小分子與中國人胰腺癌的治療
[2]人BMP10活性蛋白的表達鑑定及其在心臟保護方面的套用
[3]藥物高通量篩選平台的構建-與美國Origene公司的合作
[4]長效糖尿病治療創新藥物GLP-1的研製及產業化研究
[5]DNA修復酶PNKP與腫瘤耐藥的相關性研究
近年來輔導發表論文
1.Chen Shuxian, Wang Xu, Ye Xianghui,Gong xiaohai, et al. Identification of human UMP/CMP kinase 1 as doxorubicin binding target using protein microarray.J Biomol Screen, 2017, 22: 1007-1015.
2.Fu Qianyun, Chen Zhen,Gong Xiaohai, et al. β-Catenin expression is regulated by an IRES-dependent mechanism and stimulated by paclitaxel in human ovarian cancer cells.Biochem and Bioph Res Co, 2015, 416: 21-27.
3.Qian Kai,Gong Xiaohai, Guan Bo, et al. Efficient expression of glucagon-like peptide-1 analogue with human serum albumin fusion protein in Pichia pastoris using the glyceraldehyde-3-phosphate dehydrogenase promoter.Biotechnol Bioproc E, 2015, 20: 694-700.
4.Qian Kai, Li Chengyuan,Gong Xiaohai, et al. Expression of a glucagon-like peptide-1 analogue, as a therapeutic agent for type II diabetes, with enhanced bioactivity and increased N-terminal homogeneity in Pichia pastoris. Biotechnol Lett, 2015, 37: 2229–2235.
5.Yang Xueli, Ndawula Jr Charles, Zhou Haiyan,Gong Xiaohai, Jin Jian. JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib. Oncol lett, 2015, 9: 757-761.
6.Charles Ndawula Jr., Xueli Yang,XiaohaiGong, Jian Jin CHK21100delC, I157T, IVS2 +IG ＞ A, BRCA1 and BRCA2 Mutation Analysis in JF305: A Pancreatic Cancer Cell LineJournal of Biosciences and Medicines, 2014, 2, 58-67
7.Xueli Yang, Charles Ndawula, Haiyan Zhou,Xiaohai Gong, Jian Jin JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib.Oncol Lett2015 Feb 3;9(2):757-761.
8.Muhammad Imran Amirzada, Xin Ma,Xiaohai Gong, Yun Chen, Sajid Bashir, Jian Jin Recombinant human interleukin 24 reverses Adriamycin resistance in a human breast cancer cell line.Pharmacol Rep2014 Oct 6;66(5):915-9.
9.Muhammad Imran Amirzada, Minglei Yu,Xiaohai Gong, Yun Chen, Ruiyu Zhu, Jianyong Lei, Jian Jin Cost-effective production of recombinant human interleukin 24 by lactose induction and a two-step denaturing and one-step refolding method.J Ind Microbiol Biotechnol2014 Jan 31;41(1):135-42.
10.Haiyan Zhou, Jun Ma, Xueli Yang,Xiaohai Gong, Qiuping Li, Jian Jin Expression and purification of hPARP1 by baculovirus system.Sheng Wu Gong Cheng Xue Bao2013 Jul;29(7):998-1005
11.Bo Guan, Jianyong Lei, Shuai Su, Fengxiang Chen, Zuoying Duan, Yun Chen,Xiaohai Gong, Huazhong Li, Jian Jin Absence of Yps7p, a putative glycosylphosphatidylinositol-linked aspartyl protease in Pichia pastoris, results in aberrant cell wall composition and increased osmotic stress resistance.FEMS Yeast Res2012 Dec 25;12(8):969-79.
12.Robert L. Martone, Hua Zhou, Kevin Atchison, Thomas Comery, Jane Z. Xu, Xinyi Huang,Xioahai Gong,Mei Jin, Anthony Kreft, Boyd Harrison, Scott Mayer, Suzan Aschmies, Cathleen Gonzales, Margaret Zaleska, Davidc R. Riddell, Erik Wagner, Peimin Lu, Roy Sun, June Sonnenberg-Reines, Aram Oganesian, Karissa Adkins, Donna Huryn, Magid Abou-Gharbia, Ronald Magolda, Jonathan Bard, Jeffrey Paul, Glen Frick, Sangeeta Raje, S. Bradley Forlow, Carrie Balliet, Michael E. Burzynski, Peter Reinhart, Hong L. Wan, Menelas N. Pangalos, J. Steven Jacobsen* GSI-953 (Begacestat): A novel, selective thiophene sulfonamide inhibitor of APP γ-secretase for the treatment of Alzheimer’s diseaseJournal of Pharmacology and Experimental Therapeutics2009, 331:598–608
13.Jie Zhang , Diana Chen ,Xiaohai Gong ,Huaiping Ling , Guoming Zhang , Andrew Wood , Julia Heinrich , Seongeun Cho Cyclic-AMP Response Element-Based Signaling Assays for Characterization of Trk Family Tyrosine Kinases Modulators.Neurosignals, 2006 Jul 6;15 (1): 26-39
14.Feng Liu,Xiaohai Gong,Guoming Zhang, Karen Marquis, Peter Reinhart and Terrance H. Andree The inhibition of glycogen synthase kinase 3b by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Apeptides.Journal of Neurochemistry,2005, 95, 1363–1372
